April 24, 2018 / 11:11 AM / a month ago

Biogen quarterly profit jumps on higher Spinraza sales

April 24 (Reuters) - Drug developer Biogen Inc reported a 57 percent jump in quarterly profit on Tuesday, helped by higher sales of its spinal muscular atrophy drug, Spinraza.

Net income attributable to shareholders rose to $1.17 billion in the first quarter ended March 31, or $5.54 per share, from $747.6 million or $3.46 a share, a year earlier.

Revenue rose to $3.13 billion from $2.81 billion. (Reporting by Mrinalini Krothapalli; Editing by Amrutha Gayathri)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below